FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

wasnington,	D.C. 20549	

STATEMENT	OF	CHANGES IN	BENEFICIAL	OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Siatis Perry C				2. Issuer Name and Ticker or Trading Symbol AbbVie Inc. [ABBV]								neck all D	applio irecto	r 10% O		wner			
(Last)	(Fi		Middle)		3. Date of Earliest Transaction (Month/Day/Year) 04/03/2023							A b	Officer (give title below) EVP, GC AND SECRETARY						
(Street) NORTH CHICAC	GO IL	. (60064		4. li	f Amer	ndmer	nt, Date o	of Origina	I Filed	d (Month/D	ay/Year)	6. Liı	ie) <mark>X</mark> F	orm f	iled by One iled by Mor	e Repo	g (Check Ap orting Person One Repo	n
(City)	(S	ate) (Zip)		Ru	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a satisfy the affirmative defense conditions of Rule 10b5-1(c). See Ins					ant to a co								
		Tab	le I - No	n-Deriv	ative	Sec	uriti	ies Ac	quired	, Dis	posed o	of, or Be	neficia	lly Ov	vnec	I			
1. Title of Security (Instr. 3) 2. Transa Date (Month/Di			Execution Date,		Transaction Disposed Code (Instr.		ties Acquired (A) or I Of (D) (Instr. 3, 4 a		and 5) Securitie Benefici Owned F		es Fo ially (D) Following (I)		n: Direct r Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)					
								v	Amount	(A) or (D)	Price	Reported Transact (Instr. 3		tion(s)			(111501.4)		
Common Stock, \$0.01 par value 04/03/		/2023	2023		М		3,520	A	\$105	92	13,897			D					
Common Stock, \$0.01 par value 04/03/2			/2023	2023			S	S 3		3,520 D \$		0 10,377		,377		D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
Derivative Conversion Date Execution Date, T Security or Exercise (Month/Day/Year) if any C				ransaction of Code (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)				
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares						
Option (Right to buy) ⁽¹⁾	\$105.92	04/03/2023			M			3,520	02/18/20	22	02/17/2031	Common Stock	3,520	\$105	5.92	3,520		D	

Explanation of Responses:

1. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

Remarks:

The option exercise and sale transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).

Steven L. Scrogham, attorneyin-fact for Perry C. Siatis

04/05/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.